Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.

Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R.

Clin Lymphoma Myeloma Leuk. 2020 Jan 14. pii: S2152-2650(20)30039-2. doi: 10.1016/j.clml.2020.01.003. [Epub ahead of print]

PMID:
32044274
2.

Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.

Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Ali NA, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, Sallman DA, Cluzeau T.

Eur J Haematol. 2020 Jan 28. doi: 10.1111/ejh.13390. [Epub ahead of print]

PMID:
31990086
3.

Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.

Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R.

J Clin Invest. 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review.

4.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.

N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.

PMID:
31914241
5.

Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.

Badaat I, Mirza S, Padron E, Sallman D, Komrokji R, Song J, Hussaini MO.

J Clin Pathol. 2019 Nov 26. pii: jclinpath-2019-206132. doi: 10.1136/jclinpath-2019-206132. [Epub ahead of print]

PMID:
31771970
6.

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP.

JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00119. Epub 2019 Sep 20.

7.

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE.

Clin Cancer Res. 2020 Jan 1;26(1):54-60. doi: 10.1158/1078-0432.CCR-19-2169. Epub 2019 Oct 21.

PMID:
31636097
8.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2020 Jan;95(1):E1-E3. doi: 10.1002/ajh.25644. Epub 2019 Nov 1. No abstract available.

PMID:
31588594
9.

Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.

Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN.

Clin Pharmacol Ther. 2020 Mar;107(3):563-570. doi: 10.1002/cpt.1641. Epub 2019 Nov 1.

PMID:
31549389
10.

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A.

Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3.

PMID:
31481511
11.

Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study.

Kis B, Mills M, Smith J, Choi J, Sagatys E, Komrokji R, Strosberg J, Kim RD.

J Vasc Interv Radiol. 2019 Aug 27. pii: S1051-0443(19)30541-X. doi: 10.1016/j.jvir.2019.05.031. [Epub ahead of print]

PMID:
31471193
12.

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10. No abstract available.

PMID:
31444809
13.

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.

PMID:
31357093
14.

Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience.

Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M.

Thromb J. 2019 Jul 2;17:13. doi: 10.1186/s12959-019-0202-z. eCollection 2019.

15.

Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.

Komrokji RS.

Curr Hematol Malig Rep. 2019 Aug;14(4):346-351. doi: 10.1007/s11899-019-00517-9. Review.

PMID:
31203517
16.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

17.

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK.

Leuk Lymphoma. 2019 Dec;60(13):3161-3171. doi: 10.1080/10428194.2019.1616186. Epub 2019 May 21.

PMID:
31111762
18.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.

Talati C, Dhulipala VC, Extermann MT, Ali NA, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE.

Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.

19.

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.

Leuk Res. 2019 Jun;81:56-61. doi: 10.1016/j.leukres.2019.03.008. Epub 2019 Mar 30.

PMID:
31030089
20.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G.

Blood Adv. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989.

21.

Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.

Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, Lis AF.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):251-254. doi: 10.1016/j.clml.2018.12.014. Epub 2019 Jan 2.

PMID:
30852241
22.

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.

Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):157-161. doi: 10.1016/j.clml.2018.12.005. Epub 2018 Dec 20.

PMID:
30713125
23.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

24.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
25.

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).

Smith BN, Savona M, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):1-8. doi: 10.1016/j.clml.2018.11.019. Epub 2018 Nov 23. Review.

PMID:
30555034
26.

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.

27.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

28.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA.

Cancer. 2018 Dec 15;124(24):4601-4609. doi: 10.1002/cncr.31769. Epub 2018 Oct 5.

29.

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.

Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. No abstract available.

30.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T.

Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529.

31.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF.

Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30.

32.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.

Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G.

Am J Hematol. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26.

33.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

34.

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.

Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E.

Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19.

PMID:
30026572
35.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. No abstract available.

PMID:
29963936
36.

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):528-532. doi: 10.1016/j.clml.2018.05.016. Epub 2018 May 26.

PMID:
29937400
37.

Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.

Shammo JM, Komrokji RS.

Expert Rev Hematol. 2018 Jul;11(7):577-586. doi: 10.1080/17474086.2018.1486188. Epub 2018 Jun 19. Review.

PMID:
29902097
38.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
39.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

40.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Nov;59(11):2723-2726. doi: 10.1080/10428194.2018.1452219. Epub 2018 Apr 18. No abstract available.

PMID:
29667455
41.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK.

Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16. No abstract available.

42.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9.

43.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

44.

Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.

Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J.

Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):121-126.

45.

Azacitidine Use for Myeloid Neoplasms.

El Fakih R, Komrokji R, Shaheen M, Almohareb F, Rasheed W, Hassanein M.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e147-e155. doi: 10.1016/j.clml.2018.02.005. Epub 2018 Feb 8. Review.

PMID:
29478947
46.

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Br J Haematol. 2019 Feb;184(3):450-455. doi: 10.1111/bjh.15099. Epub 2018 Jan 23. No abstract available.

PMID:
29359794
47.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
48.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G.

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. No abstract available.

49.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
50.

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J.

Blood Cancer J. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0. No abstract available.

Supplemental Content

Loading ...
Support Center